With 1.39 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.45 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.94 whereas the lowest price it dropped to was $1.83. The 52-week range on ERAS shows that it touched its highest point at $3.45 and its lowest point at $1.64 during that stretch. It currently has a 1-year price target of $5.00. Beta for the stock currently stands at 1.22.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ERAS was down-trending over the past week, with a drop of -21.78%, but this was down by -29.39% over a month. Three-month performance dropped to -35.09% while six-month performance fell -38.74%. The stock gained 1.65% in the past year, while it has lost -26.29% so far this year. A look at the trailing 12-month EPS for ERAS yields -0.83 with Next year EPS estimates of -0.60. For the next quarter, that number is -0.13. This implies an EPS growth rate of 10.85% for this year and 18.44% for next year.
Float and Shares Shorts:
At present, 282.69 million ERAS shares are outstanding with a float of 163.43 million shares on hand for trading. On 2024-12-31, short shares totaled 32.79 million, which was 1160.0000400000001 higher than short shares on 1732838400. In addition to Dr. Jonathan E. Lim M.D. as the firm’s Co-Founder, Chairman & CEO, Dr. David M. Chacko M.D. serves as its CFO & Chief Business Officer.
Institutional Ownership:
Through their ownership of 0.87027 of ERAS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ERAS reported revenue of $0.0 and operating income of -$37242000.0. The EBITDA in the recently reported quarter was -$36400000.0 and diluted EPS was -$0.11.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ERAS since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ERAS analysts setting a high price target of 7.0 and a low target of 3.5, the average target price over the next 12 months is 5.0. Based on these targets, ERAS could surge 278.38% to reach the target high and rise by 89.19% to reach the target low. Reaching the average price target will result in a growth of 170.27% from current levels.
Analysts have provided yearly estimates in a range of -$0.69938 being high and -$0.85141 being low. For ERAS, this leads to a yearly average estimate of -$0.73992. Based on analyst estimates, the high estimate for the next quarter is -$0.12 and the low estimate is -$0.16. The average estimate for the next quarter is thus -$0.14.
